Skip to content

Thursday, May 15, 2025

Latest:

AI tool helps identify ‘who’s talking’ in the cerebellum
Brewed awakening: you might be drinking too much caffeine
The evolution of breast implants: from Houston’s origins to cutting-edge innovations
Dr. Margaret Goodell elected to the National Academy of Sciences
Healthy Habits: Dr. Samer Mattar enjoys walking on the treadmill

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

endocrine therapy

Interferon linked to ER+/HER- metastatic breast cancer resistance to therapy

March 12, 2021 CDK4/6 inhibitor therapy, endocrine therapy, ER+/HER2- breast cancer, Interferon, Metastatic breast cancer, Research, resistance to cancr treatment

Both preclinical models and tumor samples from patients with ER+/HER2- breast cancer link high IFN signaling to resistance to treatment.

From the Labs: Image of the Month

From the Labs: a closer look at metastatic medulloblastoma

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951

	
		OSZAR »